{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:58:00Z","timestamp":1787885880198,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Androgenetic alopecia (AGA) is the most common cause of hair loss in both genders with a higher psychological impact on females. Currently, topical minoxidil is the only FDA-approved treatment for female AGA and it needs life-long application and causes side effects. Cetirizine is an antihistamine that may be effective in hair loss treatment. This study aimed to compare the efficacy and safety of topical cetirizine with minoxidil (group 1) versus topical minoxidil with placebo (group 2) in female patients with AGA. This was a double-blind, randomized, controlled, parallel study conducted at Dermatology Clinic, Cairo University Teaching Hospital (Kasr- Al- Ainy), Egypt. Sixty-six patients with female AGA, aged 20\u201350\u00a0years, Sinclair (II\u2013IV), were randomly assigned to one of the 2 groups for 24\u00a0weeks. The trichoscopic parameters, patients\u2019 self-assessment, side effects and global photographic assessment were evaluated. There was a statistically significant change from baseline in frontal and vertex terminal and vellus hair density (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0005) with a significant increase in vertex hair shaft thickness and average number\u00a0of hairs per follicular unit in group 1 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Patients reported significantly better scores in patient self-assessment in group 1 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Side effects were not significantly different between groups (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). Topical cetirizine increases hair shaft thickness and results in a higher clinical improvement from patients\u2019 perspective with a good safety profile (NCT04481412, study start date: July 2020).<\/jats:p>","DOI":"10.1007\/s00403-022-02512-2","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T08:02:35Z","timestamp":1672041755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study"],"prefix":"10.1007","author":[{"given":"Eglal A.","family":"Bassiouny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solwan I.","family":"El-Samanoudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie M.","family":"Abbassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan R.","family":"Nada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar F.","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"issue":"3","key":"2512_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1365-2133.1992.tb00121.x","volume":"127","author":"C Jaworsky","year":"1992","unstructured":"Jaworsky C, Kligman AM, Murphy GF (1992) Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol 127(3):239\u2013246. https:\/\/doi.org\/10.1111\/j.1365-2133.1992.tb00121.x","journal-title":"Br J Dermatol"},{"issue":"2","key":"2512_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/107555302317371433","volume":"8","author":"N Prager","year":"2006","unstructured":"Prager N, Bickett K, French N (2006) A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med 8(2):143\u2013152","journal-title":"J Altern Complement Med"},{"key":"2512_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003122","author":"LA Garza","year":"2012","unstructured":"Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L, Ahluwalia G, Fischer SM, FitzGerald GA, Cotsarelis G (2012) Prostaglandin D 2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3003122","journal-title":"Sci Transl Med"},{"key":"2512_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0531-5565(02)00093-1","volume":"37","author":"R Trueb","year":"2002","unstructured":"Trueb R (2002) Molecular mechanisms of androgenetic alopecia. Exp Gerontol 37:981\u2013990","journal-title":"Exp Gerontol"},{"issue":"5","key":"2512_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/j.1365-2133.2010.09661.x","volume":"162","author":"P Cousen","year":"2010","unstructured":"Cousen P, Messenger A (2010) Female pattern hair loss in complete androgen insensitivity syndrome. Br J Dermatol 162(5):1135\u20131137. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09661.x","journal-title":"Br J Dermatol"},{"issue":"1","key":"2512_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40257-019-00479-x","volume":"21","author":"M Starace","year":"2020","unstructured":"Starace M, Orlando G, Alessandrini A, Piraccini BM (2020) Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol 21(1):69\u201384. https:\/\/doi.org\/10.1007\/s40257-019-00479-x","journal-title":"Am J Clin Dermatol"},{"key":"2512_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/0190-9622(93)70223-G","volume":"29","author":"TF Cash","year":"1993","unstructured":"Cash TF, Price VH, Savin RC (1993) Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol 29:568\u2013575","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2512_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0277-9536(94)90311-5","volume":"38","author":"J Van der Donk","year":"1994","unstructured":"Van der Donk J, Hunfeld JA, Passchier J, Knegt-Junk KJ, Nieboer C (1994) Quality of life and maladjustment associated with hair loss in women with alopecia androgenetica. Soc Sci Med 38(1):159\u2013163","journal-title":"Soc Sci Med"},{"key":"2512_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1365-2133.1991.tb14749.x","volume":"125","author":"J Van der Donk","year":"1991","unstructured":"Van der Donk J, Passchier J, Knegt-Junk C, Van der Wegen-Keijser MH, Nieboer C, Stolz E, Verhage F (1991) Psycho-logical characteristics of women with androgenetic alopecia: a controlled study. Br J Dermatol 125:248\u2013252","journal-title":"Br J Dermatol"},{"issue":"4","key":"2512_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2003.06.014","volume":"50","author":"AW Lucky","year":"2004","unstructured":"Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD, Kohut BE (2004) A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 50(4):541\u2013553. https:\/\/doi.org\/10.1016\/j.jaad.2003.06.014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2512_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1067\/mjd.2002.124088","volume":"47","author":"EA Olsen","year":"2002","unstructured":"Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ (2002) A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 47(3):377\u2013385. https:\/\/doi.org\/10.1067\/mjd.2002.124088","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2512_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1517\/13543784.2013.784743","volume":"22","author":"IC Valente Duarte de Sousa","year":"2013","unstructured":"Valente Duarte de Sousa IC, Tosti A (2013) New investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs 22(5):573\u2013589","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"2512_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0091-6749(89)90104-8","volume":"83","author":"EN Charlesworth","year":"1989","unstructured":"Charlesworth EN, Kagey-Sobotka A, Norman PS, Lichtenstein LM (1989) Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 83(5):905\u2013912. https:\/\/doi.org\/10.1016\/0091-6749(89)90104-8","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"2512_CR14","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.2174\/092986708785747625","volume":"15","author":"C Chen","year":"2008","unstructured":"Chen C (2008) Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem 15(21):2173\u20132191. https:\/\/doi.org\/10.2174\/092986708785747625","journal-title":"Curr Med Chem"},{"key":"2512_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13940","author":"MS Zaky","year":"2021","unstructured":"Zaky MS, Abo Khodeir H, Ahmed HA, Elsaie ML (2021) Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: a case-controlled study. J Cosmet Dermatol. https:\/\/doi.org\/10.1111\/jocd.13940","journal-title":"J Cosmet Dermatol"},{"key":"2512_CR16","doi-asserted-by":"publisher","DOI":"10.18433\/jpps31456","author":"DH Mostafa","year":"2021","unstructured":"Mostafa DH, Samadi A, Niknam S, Nasrollahi SA, Guishard A, Firooz A (2021) Efficacy of cetirizine 1% versus minoxidil 5% topical solution in the treatment of male alopecia: a randomized, single-blind controlled study. J Pharm Pharm Sci. https:\/\/doi.org\/10.18433\/jpps31456","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"2512_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/09546634.2017.1341610","volume":"29","author":"A Rossi","year":"2018","unstructured":"Rossi A, Campo D, Fortuna MC, Garelli V, Pranteda G, De Vita G, Sorriso-Valvo L, Di Nunno D, Carlesimo M (2018) A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatol Treat 29(2):149\u2013151. https:\/\/doi.org\/10.1080\/09546634.2017.1341610","journal-title":"J Dermatol Treat"},{"key":"2512_CR18","unstructured":"Sealed Envelope Ltd. (2021) Create a blocked randomisation list. https:\/\/www.sealedenvelope.com\/simple-randomiser\/v1\/lists. [accessed September 28, 2021]."},{"key":"2512_CR19","unstructured":"(2022) Fotofinder. https:\/\/www.fotofinder.de\/en\/company\/about-us. [accessed November 11, 2022]"},{"issue":"1","key":"2512_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3315\/jdcr.2008.1021","volume":"3","author":"A Rakowska","year":"2009","unstructured":"Rakowska A (2009) Trichoscopy (hair and scalp videodermoscopy) in the healthy female. Method standardization and norms for measurable parameters. J Dermatol Case Rep 3(1):14\u201319. https:\/\/doi.org\/10.3315\/jdcr.2008.1021","journal-title":"J Dermatol Case Rep"},{"issue":"3","key":"2512_CR21","first-page":"100","volume":"60","author":"J Harness","year":"2009","unstructured":"Harness J, Mamolo C, Olsen E, Price V (2009) The women\u2019s hair growth questionnaire: development and validation of a patient-reported measure for treatment efficacy in androgenetic alopecia. J Am Acad Dermatol 60(3):100","journal-title":"J Am Acad Dermatol"},{"key":"2512_CR22","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2147\/PPA.S282399","volume":"15","author":"K Thadanipon","year":"2021","unstructured":"Thadanipon K, Suchonwanit P (2021) Measuring patient quality of life following treatment for alopecia. Patient Prefer Adherence 15:1601\u20131610. https:\/\/doi.org\/10.2147\/PPA.S282399","journal-title":"Patient Prefer Adherence"},{"key":"2512_CR23","unstructured":"Universitat Dusseldorf. (2021) G-power. http:\/\/www.psychologie.hhu.de\/arbeitsgruppen\/allgemeine-psychologie-und-arbeitspsychologie\/gpower.html. [accessed September 28, 2021]."},{"issue":"2","key":"2512_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/jdv.13864","volume":"31","author":"A Rossi","year":"2017","unstructured":"Rossi A, Miraglia E, Fortuna MC, Calvieri S, Giustini S (2017) Topical cetirizine and oral vitamin D: a valid treatment for hypotrichosis caused by ectodermal dysplasia. J Eur Acad Dermatology Venereol 31(2):367\u2013370. https:\/\/doi.org\/10.1111\/jdv.13864","journal-title":"J Eur Acad Dermatology Venereol"},{"issue":"2","key":"2512_CR25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/1078155220930334","volume":"27","author":"G Caro","year":"2021","unstructured":"Caro G, Fortuna MC, Magri F, Federico A, Carlesimo M, Rossi A (2021) A new treatment of alopecia induced by palbociclib: topical cetirizine. J Oncol Pharm Pract 27(2):460\u2013463. https:\/\/doi.org\/10.1177\/1078155220930334","journal-title":"J Oncol Pharm Pract"},{"key":"2512_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2133.1977.tb15179.x","volume":"97","author":"E Ludwig","year":"2022","unstructured":"Ludwig E (2022) Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 97:247\u2013254","journal-title":"Br J Dermatol"},{"issue":"9","key":"2512_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/lsm.22684","volume":"49","author":"SM Esmat","year":"2017","unstructured":"Esmat SM, Hegazy RA, Gawdat HI, Abdel Hay RM, Allam RS, El Naggar R, Moneib H (2017) Low level light-minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: a randomized controlled study. Lasers Surg Med 49(9):835\u2013843.\u00a0https:\/\/doi.org\/10.1002\/lsm.22684","journal-title":"Lasers Surg Med"},{"issue":"3","key":"2512_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.mjafi.2020.11.010","volume":"77","author":"R Ray","year":"2021","unstructured":"Ray R, Sharma A (2021) Comparison of 5% minoxidil lotion monotherapy versus its combination with autologous platelet rich plasma in androgenetic alopecia in hundred males. Med J Armed Forces India 77(3):355\u2013362. https:\/\/doi.org\/10.1016\/j.mjafi.2020.11.010","journal-title":"Med J Armed Forces India"},{"issue":"20","key":"2512_CR29","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World medical association declaration of Helsinki. JAMA 310(20):2191. https:\/\/doi.org\/10.1001\/jama.2013.281053","journal-title":"JAMA"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02512-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-022-02512-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02512-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T08:07:11Z","timestamp":1672042031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-022-02512-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":29,"alternative-id":["2512"],"URL":"https:\/\/doi.org\/10.1007\/s00403-022-02512-2","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki, and the study protocol (CL 2555) was approved by the Research Ethics Committee for Experimental and Clinical Studies, Faculty of Pharmacy, Cairo University. The study was registered in clinicaltrials.gov, identifier number NCT04481412.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Oral and written informed consents were obtained from all patients before enrollment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}]}}